ZBH Stock Recent News

Zimmer Biomet: Weight Loss Drug Concerns Are Overblown

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.

Zimmer Biomet is focusing on growth acceleration after spinning off divisions and refocusing on high-growth areas in the medical device market. The company's growth target is supported by investments in R&D for new product launches and strategic targeting of high-growth markets. Zimmer's ROSA system holds promise for accelerating growth in the Total Knee segment and tapping into an underpenetrated market with substantial growth potential.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.

Zimmer Biomet has seen a strong operating performance despite years of stagnation, making its shares compelling. The company's valuation has become more reasonable, with revenues trending at around $7.3 billion and adjusted earnings reported at $7.50 per share. The impact of GLP-1 drugs on demand for Zimmer Biomet's products raises concerns about future growth.

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.65 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.58 per share a year ago.

Zimmer Biomet Holdings Inc on Tuesday beat Wall Street estimates for third-quarter profit, as a rebound in knee surgeries lifted demand for the medical device maker's products.